• Andrew M, Boyle D, Coupar B. Vaccina virus recombinants expressing the SA11 rotavirus VP7 glycopro-tein gene induce serotype specific neutralizing antibodies[J]. J Virol, 1987, 61(4): 1054-1060.

  • Barril P, Martinez L, Giordano M. Detection of group A human rotavirus G9 genotype circulating in Cordoba, Argentina, as early as 1980[J]. J Med Virol, 1980, 78(8): 1113-1118.

  • Cao Z, Wen Y, Chen Y. Cloning and high level expression of Vp6 gene from group A human rotavirus in E.coli.[J]. China Biotechnol, 2006, 26(3): 37-41.

  • Chen Y, Liu M, Zhao W. Broadly immunological reactivities primed by epitopes corresponding to the cleavage region of SA11 Vp4[J]. Virologica Sinica, 1998, 13(1): 57-63.

  • Ciarlet M, Crawford S, Barone C. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity[J]. J Virol, 1998, 72(11): 9233-9246.

  • Clark S, Roth M, Clark B. Trypsin enhancement of rotavirus infectivity: mechanism of enhancement[J]. J Virol, 1981, 39(): 816-822.

  • Estes K, Ohen J. Rotavirus gene structure and function[J]. Microbiol Rev, 1989, 53(4): 410-449.

  • Gorziglia M, Kapikian A. Expressing of the OSU rotavirus outer capsid protein VP4 by an adenovirus recombinant[J]. J Virol, 1992, 66(7): 4407-4412.

  • Huo Y, Qian Y, Li G. Sequence analysis and prokaryotic expression full length VP4 gene of rotavirus Group A[J]. Chin J Pediat, 1999, 37(11): 680-683.

  • Li W, Ouyang F. Hofmeister effect and incluision bodies denaturation and renaturation[J]. Biotechnol Inform, 2000, 4(): 37-40.

  • Liu X, Yang T, Sun Q. Efficient intranasal immunization of new born mice with recombinant adenovirus expressing rotavirus protein VP4 against oral rotavirus infection[J]. Acta Virol, 2005, 49(1): 17-22.

  • Mackow E, Barnett J, Chan H. The rhesus rotavirus outer protein VP4 function as a hemmagglutinin and is antigenically conserved when expressed by a baculovirus recombinant[J]. J Virol, 1989, 63(4): 1661-1668.

  • Mcneal M M, Rae M N, Bean J A. Antibodydependent and-independent protection following intranasal immunization of mice with rotavirus like particles[J]. J Virol, 1999, 73(9): 7565-7573.

  • Mori Y, Sugiyama M, Takayama M. Avianto-mammal transmission of an avian rotavirus: analysis of its pathogenicity in a heterologous mouse model[J]. Virology, 2001, 288(1): 63-70. doi: 10.1006/viro.2001.1051

  • Parashar U, Humelman E, Bresee J. Global illness and deaths caused by rotavirus disease in children[J]. Emerg Infect Dis, 2003, 9(5): 565-572. doi: 10.3201/eid0905.020562

  • Redmond M J, Ijaz M K, Parker M D. Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential[J]. Vaccine, 1993, 11(2): 273-281. doi: 10.1016/0264-410X(93)90029-W

  • Sarah E, Blutt , Kelly L. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and viral like particles (VLPs)[J]. Vaccine, 2006, 24(8): 1170-1179. doi: 10.1016/j.vaccine.2005.08.090

  • Yoder J, Dormitzer P. Alternative intermolecular contacts underlie the rotavirus Vp5* two-to three-fold rearrangemen[J]. EMBO J, 2006, 25(7): 1559-1568. doi: 10.1038/sj.emboj.7601034